MXCT - MaxCyte, Inc. So'nggi Yangiliklar | Finranks

MXCT - MaxCyte, Inc. So'nggi Yangiliklar | Finranks

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates

MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.1 per share a year ago.

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in t otal cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md.

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025.

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of ExPERT DTx™, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines with minimal cellular stress, helping researchers to uncover valuable insights and better understand fundamental biological processes before scaling up to larger transfection volumes.

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2025.

Videolar

No Data

There is no data to display